Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The Heartmate 3 (HM3) risk score (HM3RS) was derived and validated internally from within the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) trial population and provides 1- and 2-year mortality risk prediction for patients in those before HM3 left ventricular assist device (LVAD) implantation. We aimed to evaluate the HM3RS in nontrial unselected patients, including those not meeting inclusion criteria for MOMENTUM 3 trial enrollment.
Methods: Patients who underwent HM3 LVAD implant at 1 of 7 US centers between 2017 and 2021, with at least 1-year follow-up, were included in this analysis. Patients were retrospectively assessed for their eligibility for the MOMENTUM 3 trial based on study inclusion and exclusion criteria. HM3RS risk discrimination was evaluated using time-dependent receiver operating characteristic curve analysis for 1-year mortality for all patients and further stratified by MOMENTUM 3 trial eligibility. Kaplan-Meier curves were constructed using the HM3RS-based risk categories.
Results: Of 521 patients included in the analysis, 266 (51.1%) would have met enrollment criteria for MOMENTUM 3. The 1- and 2-year survival for the total cohort was 85% and 81%, respectively. There was no statistically significant difference in survival between those who met and did not meet enrollment criteria at 1 (87% vs 83%; p = 0.21) and 2 years postimplant (80% vs 78%; p = 0.39). For the total cohort, HM3RS predicted 1-year survival with an area under the curve (AUC) of 0.63 (95% confidence interval [CI]: 0.57-0.69, p < 0.001). HM3RS performed better in the subset of patients meeting enrollment criteria: AUC 0.69 (95% CI:0.61-0.77, p < 0.001) compared to the subset that did not: AUC 0.58 (95% CI: 0.49-0.66, p = 0.078).
Conclusions: In this real-world evidence, multicenter cohort, 1- and 2-year survival after commercial HM3 LVAD implant was excellent, regardless of trial eligibility. The HM3RS provided adequate risk discrimination in "trial-like" patients, but predictive value was reduced in patients who did not meet trial criteria.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.healun.2023.11.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Mild and Moderate Aortic Stenosis in Acute Heart Failure: Insights from RELAX-AHF-2.
J Card Fail
August 2025
University of Groningen, University Medical Centre Groningen, Department of Cardiology and Cardiothoracic Surgery, Heart Centre. Electronic address:
Background: Aortic stenosis leads to increased afterload, which may be detrimental in a failing left ventricle and has been associated with increased risk of heart failure hospitalizations and mortality in chronic heart failure. The prevalence and impact of aortic stenosis in acute heart failure is less well described. This post hoc analysis aimed to evaluate the prevalence and prognostic impact of aortic stenosis in a large cohort of patients hospitalized with acute heart failure.
View Article and Find Full Text PDFNonregistration, Discontinuation, and Nonpublication of Randomized Trials: A Systematic Review.
JAMA Netw Open
September 2025
Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Importance: Previous work found that 25% to 30% of randomized clinical trials (RCTs) with protocols approved in 2012 or between 2000 and 2003 were discontinued prematurely, most commonly due to inadequate participant recruitment. To minimize research waste, RCTs should be registered and their results made available.
Objectives: To assess the fate of RCTs approved by ethics committees in 2016 in terms of nonregistration, discontinuation, and nonpublication, and to examine RCT characteristics associated with discontinuation due to poor recruitment and nonpublication of RCT results.
Immunogenicity and safety of self-amplifying mRNA COVID-19 vaccine (ARCT-2303), with or without co-administration of seasonal inactivated influenza vaccine in adults: a phase 3, randomised, controlled, observer-blind, multicentre study.
EClinicalMedicine
September 2025
Arcturus Therapeutics, San Diego, USA.
Background: A recently licenced self-amplifying mRNA (sa-mRNA) COVID-19 vaccine induces a robust, broad, and long-lasting immune response, extending the arsenal of efficacious COVID-19 countermeasures. We ran a clinical study to assess the benefits of vaccine strain update and the feasibility of co-administration with influenza vaccines.
Methods: Between March 27, 2024 and April 10, 2025, we performed a randomised, observer-blind, placebo-controlled, phase 3 study with 1499 adult participants to compare immune responses of sa-mRNA vaccine, encoding spike glycoprotein of the XBB.
Hypertensive acute heart failure: a critical perspective on definition, epidemiology, pathophysiology, and prognosis-a narrative review: a joint session with the Romanian Society of Cardiology (part II).
Heart Fail Rev
September 2025
Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', 258 Fundeni Street, 2 District, 022328, Bucharest, Romania.
Hypertensive acute heart failure (HT-AHF) has historically been recognized as a distinct clinical phenotype of AHF, characterized by acute pulmonary congestion in the context of elevated systolic blood pressure (SBP), typically > 140 mmHg. However, emerging evidence has begun to challenge the diagnostic accuracy, clinical utility, and relevance of this category. A main criticism of HT-AHF is its considerable overlap with other AHF clinical profiles, including acute decompensated heart failure (ADHF) and acute pulmonary oedema (APO).
View Article and Find Full Text PDFThe effect of age, education, and vocabulary size on the speed of word recognition across the lifespan.
Brain Res
August 2025
Department of Cognitive Science, Budapest University of Technology and Economics, Hungary; MTA-BME Momentum Language Acquisition Research Group, Hungarian Research Network (HUN-REN), Hungary. Electronic address:
Age and language experience both shape the speed of visual word recognition for children and adults. There is a considerable debate in the literature regarding whether these effects are primarily facilitating or impeding and whether the influences of age and language experience can be distinct and delineated. In order to address these questions, we collected data from Hungarian participants, analyzing data from 80 children (ages 9-17) and 387 adults (ages 18-90), on 250 words in an online visual lexical decision task.
View Article and Find Full Text PDF